Shuda Tech, a Pathology AI Platform Under 3D Medicines, Completes Nearly RMB 10 Million Angel Funding Round

VCBeat has learned that, recently, the pathology division under 3D Medicines DiagnosisAI Platform—Shanghai Shuda Data Technology Co., Ltd. (hereinafter referred to as “Shuda Tech”) has completed its angel round of financing, securing nearly RMB 10 million in funding. This round of financing was led byMuHua Sci-Tech InnovationLead investor,Shanghai Lanshang Tingxiu Technology Service Co., Ltd.(hereinafter referred to as“Lan Shang Tingxiu”）、Shanghai Tongyang Private Equity Investment Fund Partnership (Limited Partnership)(hereinafter referred to as“Tongyang Fund”) co-invested. The funds will be invested in the research and development as well as commercial operations of Shuda Technology’s related products, injecting robust momentum into the continuous transformation of innovative achievements.

3D Medicines Diagnostics is one of the pioneering enterprises in China engaged in precision medicine, having established a multi-disciplinary R&D platform that integrates next-generation sequencing (NGS) and genomic bioinformatics, exosome technology, rapid qPCR technology, and AI-powered digital image analysis. Datafication and digitization constitute foundational pillars of precision medicine. Founded in 2023, Shanghai Shuda Data Technology Co., Ltd. is an innovative pathology AI platform incubated by 3D Medicines Diagnostics, representing a natural extension of its capabilities and data accumulation in clinical precision medicine practice.

Leveraging digital image processing technology and years of experience in pathological testing, Shuda Technology is committed to providing intelligent, end-to-end pathological image analysis solutions for medical and research professionals. Its flagship product, APTime, is a cost-effective AI-based pathological image analysis system widely used in various medical fields, including oncology, immune-mediated diseases, cardiovascular medicine, neurology, and endocrinology. Shuda Technology also provides clinical institutions with AI-driven medical image diagnostic products and comprehensive solutions, meeting unmet clinical needs with high efficiency and accuracy, thereby facilitating tiered diagnosis and treatment and promoting the decentralization of high-quality medical resources.

The lead investor in this funding round, Muhua Sci-Tech Innovation, is an innovative technology investment platform established by Muhua Education Investment Co., Ltd., a wholly-owned first-tier subsidiary of Tsinghua University Asset Management Co., Ltd. It focuses on technology investments, particularly in the artificial intelligence sector, and is also a member enterprise of the Shanghai Angel Club.

Lanshang Tingxiu, a co-investor in this financing round, is a co-investment vehicle of the Shanghai Angel Club. Tongyang Fund is a market-oriented fund jointly established by Tongji Technology (600846) and Cocoa Capital. It focuses on high-quality early- to mid-stage technology enterprises in hard-tech sectors such as intelligence and digitalization, contributing to the development of Shanghai’s new industrialization system.

Zhang Yu, Founding Partner of Movastated: “MuHua attaches great importance to the integration of artificial intelligence with vertical industries, particularly in the healthcare sector, which is characterized by data scarcity. It believes that Shanghai Shuda Data Technology Co., Ltd. can leverage 3D Medicines’ diagnostic expertise and accumulated data in pathology to develop AI products that meet market demands, thereby facilitating the intelligent transformation of China’s pathology market.”

Xiong Lei, Founder and Chairman of 3D Medicines DiagnosticsShuda Technology stated: “Shuda Technology originated from 3DMed’s internal needs for automated and intelligent processing of data and images within its precision oncology business. The company began systematically establishing its data curation services in 2015, continuously enhancing and enriching its platform capabilities, and formally established a subsidiary focused on intelligent data and image processing in 2023. As the first equity investment portfolio company following the establishment of the Shanghai Angel Club, Shuda Technology will continue to provide customers with ‘user-friendly and essential’ pathological image processing tools. Guided by the initiatives to build Shanghai into an international science and technology innovation hub and to foster the development of new quality productive forces nationwide, the company is committed to becoming the leading AI enterprise in the niche market of medical imaging.”

It is a specialized angel investment service platform, with key support from the Shanghai Institute of Sci-Tech Innovation Finance. The Shanghai Angel Club focuses on cultivating angel investors, innovating financing models, and guiding investments toward early-stage, small-scale, and hard-tech ventures. It encourages the effective utilization of existing social wealth to support technological innovation, promotes the deep integration of technological innovation with industrial entrepreneurship, and serves the development of Shanghai as an international financial center and a global science and technology innovation hub.